Sheng Liu

机构：People's Liberation Army 401 Hospital, Nanjing Medical University · ORCID：0000-0002-4058-4413

发表论文 300 篇 · 总被引 3056 次 · h-index 23

代表论文

• Gold-embedded yolk-shell mesoporous organosilica nanocomposite for microwave-enhanced targeted chemotherapy and immune modulation in hepatocellular carcinoma (2025 · Biomaterials · 被引 10)
• Thrombectomy in Stroke Patients with Large Vessel Occlusion and Mild Symptoms: Insights from a Multicenter Observational Study (2025 · Translational Stroke Research · 被引 7)
• Artificial intelligence-driven pathomics in hepatocellular carcinoma: current developments, challenges and perspectives (2025 · Discover Oncology · 被引 6)
• CT-Based Habitat Model for Predicting Tumor Response and Survival in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Combining Molecular Targeted Agents and Immune Checkpoint Inhibitors (2025 · Academic Radiology · 被引 5)
• Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancers (2025 · ESMO Open · 被引 4)
• 1329MO Enfortumab vedotin plus pembrolizumab (EV + P) as first-line (1L) treatment in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Results from a cohort of the EV-202 trial (2025 · Annals of Oncology · 被引 3)